Compare Eli Lilly And Co (LLY) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs United Microelectronics Corp — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while United Microelectronics Corp trades at $22.96 (market cap $58.02B). The key difference: Eli Lilly And Co is far larger — about 17.9× United Microelectronics Corp's market cap, and United Microelectronics Corp pays the higher dividend (1.76%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and United Microelectronics Corp for 42 Days on average.
| LLY | UMC | |
|---|---|---|
Market Cap | $1.04T | $58.02B |
Volume | 3,064,878 | 11,897,809 |
Sector | Health | Technology |
52-Week High | $1.28K | $28.02 |
52-Week Low | $799.57 | $7.02 |
Typical Hold Time | 93 Days | 42 Days |
Enterprise Value | $1.09T | $55.10B |
Dividend Yield | 0.59% | 1.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
UMC trades at $22.82, down 2.1% over the past day, with a bullish technical signal but bearish moving averages. The company reported strong recent earnings beats, with Q2 2026 EPS of $0.54 versus $0.16 expected. Revenue for 2025 was $237.55B, with a net income margin of 16.99%. Analyst consensus is mixed, with 26.67% buy ratings and 53.33% hold. Recent news highlights AI-driven growth opportunities and a DCF intrinsic value estimate of $29.
The outlook for UMC is cautiously optimistic, driven by strong earnings performance and expanding AI opportunities. Key risks include competitive pressures in the semiconductor foundry space and potential volatility from AI spending fluctuations. The stock's current valuation metrics, including a P/E of 22.03, suggest room for growth if earnings trends continue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
